“Pain Management Without Opioids: Safer Alternatives That Work”

The Problem With Relying on Opioids for Chronic Pain

Opioids are powerful analgesics for acute pain and for pain from cancer or end-of-life conditions. The evidence for their use in chronic non-cancer pain is far less supportive than many patients and physicians assumed during the prescribing surge of the 1990s and 2000s.

Long-term opioid therapy for chronic pain is associated with opioid-induced hyperalgesia, a paradoxical state in which chronic opioid use actually lowers the pain threshold and makes patients more sensitive to pain over time [1]. The mechanisms involve downregulation of endogenous opioid receptors and sensitization of pronociceptive systems. Patients who have been on opioids for years often find that reducing or stopping opioids, though difficult, actually leads to less pain in the long run.

Beyond hyperalgesia, long-term opioid use suppresses the hypothalamic-pituitary-gonadal axis, causing testosterone and estrogen deficiency in many patients, with consequences for energy, mood, sexual function, and bone density. Cognitive effects, immune suppression, constipation, and the risk of dependence and overdose complete a risk profile that warrants much greater scrutiny than opioids typically received when prescribed for chronic pain conditions [2].

None of this means that every person currently on opioids should immediately taper off. For some patients, opioids are part of a carefully monitored regimen that genuinely improves function. The question is whether patients have been offered the full range of evidence-based alternatives, many of which work through mechanisms that opioids cannot replicate.

Non-Opioid Medications That Actually Work

SNRIs: Duloxetine and Milnacipran

Duloxetine is FDA-approved for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain, including osteoarthritis. Its mechanism, enhancing descending noradrenergic and serotonergic pain inhibition, directly addresses one of the key biological drivers of chronic pain: a weakened endogenous pain-suppression system. In clinical trials for chronic low back pain, duloxetine at 60mg daily produced meaningful reductions in pain intensity and functional disability [3]. Milnacipran is similarly approved for fibromyalgia.

Gabapentinoids

Gabapentin and pregabalin reduce the hyperexcitability of pain-transmitting neurons by binding to calcium channels, limiting the excessive neuronal firing that characterizes neuropathic pain and central sensitization. They’re most effective for neuropathic pain conditions but have evidence for some non-neuropathic chronic pain as well. Pregabalin is approved for DPN, PHN, spinal cord injury pain, and fibromyalgia [4].

An important caveat: gabapentinoids are increasingly being misused and can cause dependence, particularly at higher doses. They should be used thoughtfully, titrated to the minimum effective dose, and reconsidered periodically rather than continued indefinitely by default.

Tricyclic Antidepressants

Amitriptyline and nortriptyline have decades of evidence for neuropathic pain, headache prevention, and some musculoskeletal conditions. They remain underused, partly because of their older reputation and partly because of side effects that limit tolerability at higher doses. At low doses (10 to 50mg), nortriptyline in particular has a favorable side effect profile and can be particularly helpful for patients whose pain is disrupting sleep.

Topical Analgesics

Topical treatments deserve far more use than they typically receive. Diclofenac gel delivers anti-inflammatory medication directly to musculoskeletal pain sites with systemic absorption around 6 percent of an equivalent oral dose, dramatically reducing GI and cardiovascular risks [5]. Lidocaine patches (5%) work well for localized neuropathic pain. High-concentration capsaicin patches (8%) provide up to three months of pain relief from a single application by depleting substance P from peripheral nerve endings. These options are particularly valuable for older patients where systemic medications carry higher risks.

Low-Dose Naltrexone

At conventional doses (50mg), naltrexone blocks opioid receptors for addiction treatment. At much lower doses (1 to 4.5mg), it acts through a completely different mechanism: brief blockade of opioid receptors stimulates the body to upregulate endogenous opioid production, and the drug simultaneously exerts anti-neuroinflammatory effects through toll-like receptor 4 on microglia. In a randomized controlled trial for fibromyalgia, low-dose naltrexone produced significant reductions in pain and fatigue compared to placebo [6]. It’s inexpensive, well-tolerated, and has a rationale for any pain condition with a neuroinflammatory component.

Regenerative Therapies: Treating the Source

The most compelling argument against long-term opioid therapy isn’t just the side effects. It’s that opioids do nothing to repair the damaged tissue or dysfunctional biology generating the pain. Regenerative approaches aim at the root.

Platelet-Rich Plasma (PRP)

PRP concentrates the patient’s own platelets and injects them into damaged tissue. Platelets release growth factors including PDGF, TGF-beta, VEGF, and IGF-1 that stimulate healing in tendons, cartilage, ligaments, and other structures. For knee osteoarthritis, PRP has consistently outperformed hyaluronic acid in trials measuring pain and function at 6 and 12 months, with better safety profiles than repeated corticosteroid injections [7]. For chronic tendinopathies (Achilles, patellar, lateral epicondyle), PRP has shown durable improvements in multiple randomized trials.

The clinical implication is that for a patient with knee pain from OA who has been escalating pain medications, PRP may address the structural source of the pain in a way no medication can. The pain reduction may not be immediate, but the changes in the joint are real and potentially progressive.

Prolotherapy

Dextrose prolotherapy, injecting concentrated sugar solution into damaged ligaments and tendons, triggers a controlled local inflammatory response that recruits healing cells and stimulates collagen synthesis. It’s particularly well-suited to conditions where ligament laxity or tendon degeneration is driving pain, such as chronic low back pain from sacroiliac joint or facet ligament laxity, and chronic ankle instability.

A Cochrane-level systematic review of prolotherapy for chronic low back pain found significant benefits compared to sham injection, with the strongest effects in studies using co-interventions like exercise [8]. High-volume prolotherapy protocols (Hackett-Hemwall technique) have decades of clinical use and a strong safety record.

Stem Cell and Bone Marrow Aspirate Concentrate (BMAC)

Bone marrow aspirate concentrate, containing mesenchymal stem cells and growth factors, and adipose-derived stem cells are being used for moderate-to-severe osteoarthritis and other degenerative joint conditions. Mesenchymal stem cells reduce joint inflammation through immunomodulatory mechanisms and may support cartilage repair through paracrine signaling [9]. Early clinical trials have reported significant and durable pain relief in knee OA patients who had exhausted conservative treatment. For patients facing joint replacement, stem cell injections may offer a meaningful delay or, in some cases, an alternative.

Shockwave Therapy

Extracorporeal shockwave therapy uses focused acoustic waves to stimulate healing in chronic tendinopathies, plantar fasciitis, and calcific deposits. For calcific shoulder tendinitis, shockwave is the most effective non-surgical treatment, with randomized trials demonstrating both pain reduction and actual dissolution of calcium deposits [10]. For plantar fasciitis and Achilles tendinopathy that hasn’t responded to physical therapy, shockwave provides an additional evidence-based option before considering injections or surgery.

Neuromodulation: Changing How the Brain Processes Pain

Ketamine Infusions

Ketamine remains one of the most significant developments in pain management for conditions where conventional treatments have failed. By blocking NMDA receptors in the spinal cord and brain, sub-anesthetic ketamine directly interrupts the central sensitization mechanisms that maintain chronic pain. The clinical results for complex regional pain syndrome, in particular, can be dramatic: some patients achieve prolonged remission following a series of infusions [11].

Ketamine is not a first-line treatment, but it deserves consideration much earlier in the treatment sequence for severely affected patients rather than only after years of failed trials. The window of opportunity matters: the longer central sensitization has been established, the harder it is to reverse.

Transcranial Magnetic Stimulation (TMS)

rTMS delivers focused magnetic pulses to specific brain regions. For chronic pain, targeting the motor cortex activates descending pain inhibitory pathways and reduces pain through mechanisms distinct from any medication. The accumulated evidence from controlled trials supports rTMS for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain [12]. It’s non-invasive, requires no medication, and has essentially no serious adverse events at standard protocols.

Daily sessions over two to four weeks are typically needed to produce a clinical effect, which makes it more of a committed course of treatment than a single intervention. Maintenance sessions can extend benefits in responders.

Spinal Cord Stimulation

For patients with refractory chronic pain, especially those with failed back surgery syndrome, CRPS, or refractory neuropathic pain, spinal cord stimulation (SCS) has some of the strongest evidence in interventional pain medicine. A landmark randomized trial found that SCS plus physical therapy was superior to physical therapy alone for CRPS and for failed back surgery syndrome, with SCS patients significantly more likely to achieve meaningful pain reduction and report treatment satisfaction [13].

The up-front cost and invasive nature mean SCS is appropriately reserved for refractory cases. However, it costs far less over time than years of escalating opioid therapy, specialist visits, and hospitalizations for pain crises, a comparison that is increasingly informing insurance coverage decisions.

Physical Rehabilitation and Exercise

Exercise is not a consolation prize for patients who “just need to keep moving.” It is one of the most consistently evidence-supported pain treatments across nearly all chronic pain conditions, and its mechanisms are genuinely pharmacological. Exercise activates descending pain inhibitory pathways, reduces neuroinflammation, promotes endorphin and endocannabinoid release, and reverses the central sensitization-promoting effects of physical deconditioning [14].

The key is the right type of exercise, dosed appropriately for the patient’s current capacity. Graded motor imagery and mirror therapy have specific evidence for CRPS. Aquatic exercise is often a better starting point for patients with severe deconditioning or joint pathology. Strength training has particular value for osteoarthritis-related pain. A physical therapist who understands pain neuroscience and can guide progressive loading is far more useful than a generic exercise prescription.

Peptide Therapies in Pain Management

BPC-157 and TB-500 represent an emerging area in pain management. BPC-157 has demonstrated accelerated healing of tendons, ligaments, muscle, and nerve tissue in preclinical research, alongside anti-inflammatory effects mediated through the nitric oxide system and growth hormone receptor upregulation [15]. For patients with chronic musculoskeletal pain rooted in tissue degeneration, where no convenient regenerative injection is available or accessible, BPC-157 administered systemically (subcutaneously or orally) has gained interest among regenerative medicine practitioners.

The evidence base is currently preclinical, and human clinical trials are needed. However, the mechanistic rationale is strong and the safety profile in preclinical studies has been favorable. These are areas to watch as the research matures.

Building a Non-Opioid Pain Management Plan

The most effective non-opioid pain management approaches share a common feature: they’re multimodal. A single intervention rarely provides complete relief for established chronic pain. The practical approach combines therapies addressing different mechanisms simultaneously.

For a patient with chronic low back pain, for instance, combining prolotherapy targeting the structural contributors, physical therapy addressing deconditioning and movement patterns, and duloxetine enhancing central pain modulation can collectively produce outcomes that none of these approaches achieves alone. Adding pain neuroscience education reduces catastrophizing that amplifies the central sensitization component.

For more severe or refractory pain, ketamine infusions to interrupt central sensitization, TMS to modulate brain pain networks, and ongoing physical rehabilitation create a synergistic approach. The goal throughout is not just reducing pain scores but restoring function and breaking the pain-disability-deconditioning cycle that chronic pain creates.

Patients who have been on opioids long-term should not taper abruptly or without support. A supervised taper, combined with introducing evidence-based alternatives that address the underlying pain mechanisms, gives the best chance of reducing opioid dependence while maintaining quality of life.

Related Reading

• Chronic Pain Treatment: A Complete Guide to Evidence-Based Options
• Chronic Pain Syndrome: When Pain Becomes a Disease
• Neuropathic Pain Treatment: From Medications to Regenerative Approaches
• Prolotherapy Injections: How They Work and What to Expect
• PRP Therapy: What the Research Actually Shows
• Ketamine Infusion Therapy for Pain and Depression
• Low-Dose Naltrexone: Uses and Evidence
• Transcranial Magnetic Stimulation (TMS) Therapy

References

1. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. “Do opioids induce hyperalgesia in humans? An evidence-based structured review.” Pain Med. 2009;10(5):829-839. doi:10.1111/j.1526-4637.2009.00653.x
2. Coluzzi F, Billeci D, Maggi M, Corona G. “Testosterone deficiency in non-cancer opioid-treated patients.” J Endocrinol Invest. 2018;41(12):1377-1388. doi:10.1007/s40618-018-0964-3
3. Skljarevski V, Desaiah D, Liu-Seifert H, et al. “Efficacy and safety of duloxetine in patients with chronic low back pain.” Spine (Phila Pa 1976). 2010;35(13):E578-585. doi:10.1097/BRS.0b013e3181d3cef6
4. Finnerup NB, Attal N, Haroutounian S, et al. “Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.” Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0
5. Derry S, Wiffen PJ, Kalso EA, et al. “Topical analgesics for acute and chronic pain in adults – an overview of Cochrane Reviews.” Cochrane Database Syst Rev. 2017;5(5):CD008609. doi:10.1002/14651858.CD008609.pub2
6. Younger J, Noor N, McCue R, Mackey S. “Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.” Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734
7. Dai WL, Zhou AG, Zhang H, Zhang J. “Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.” Arthroscopy. 2017;33(3):659-670. doi:10.1016/j.arthro.2016.09.024
8. Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. “A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain.” Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:139-159. doi:10.4137/CMAMD.S39160
9. Centeno C, Sheinkop M, Dodson E, et al. “A specific protocol of autologous bone marrow concentrate and platelet products versus exercise therapy for symptomatic knee osteoarthritis: a randomized controlled trial with 2 year follow-up.” J Transl Med. 2018;16(1):355. doi:10.1186/s12967-018-1736-8
10. Leal C, Ramon S, Furia J, et al. “Current concepts of shockwave therapy in chronic calcific tendinitis of the shoulder.” Int J Surg. 2015;24(Pt B):188-193. doi:10.1016/j.ijsu.2015.07.715
11. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. “Outpatient intravenous ketamine for the treatment of complex regional pain syndrome.” Pain Med. 2009;10(4):709-719. doi:10.1111/j.1526-4637.2009.00612.x
12. Lefaucheur JP, Aleman A, Baeken C, et al. “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).” Clin Neurophysiol. 2020;131(2):474-528. doi:10.1016/j.clinph.2019.11.002
13. Kumar K, Taylor RS, Jacques L, et al. “Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome.” Pain. 2007;132(1-2):179-188. doi:10.1016/j.pain.2007.07.028
14. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. “Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews.” Cochrane Database Syst Rev. 2017;4(4):CD011279. doi:10.1002/14651858.CD011279.pub3
15. Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Curr Pharm Des. 2011;17(16):1612-1632. doi:10.2174/138161211796196954